Callan Family Office LLC boosted its stake in shares of Cencora, Inc. (NYSE:COR - Free Report) by 602.6% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,070 shares of the company's stock after buying an additional 10,352 shares during the quarter. Callan Family Office LLC's holdings in Cencora were worth $2,712,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Swedbank AB raised its holdings in shares of Cencora by 2.3% in the 3rd quarter. Swedbank AB now owns 1,394,449 shares of the company's stock valued at $313,863,000 after purchasing an additional 31,104 shares in the last quarter. Harbor Capital Advisors Inc. bought a new stake in shares of Cencora in the 3rd quarter valued at about $62,000. Catalina Capital Group LLC bought a new stake in shares of Cencora in the 3rd quarter valued at about $215,000. Concurrent Investment Advisors LLC raised its holdings in shares of Cencora by 12.1% in the 3rd quarter. Concurrent Investment Advisors LLC now owns 7,697 shares of the company's stock valued at $1,732,000 after purchasing an additional 832 shares in the last quarter. Finally, Graypoint LLC raised its holdings in shares of Cencora by 7.8% in the 3rd quarter. Graypoint LLC now owns 1,171 shares of the company's stock valued at $264,000 after purchasing an additional 85 shares in the last quarter. Institutional investors own 97.52% of the company's stock.
Cencora Stock Performance
Shares of COR stock traded up $0.77 during trading hours on Friday, hitting $254.54. The company's stock had a trading volume of 2,250,571 shares, compared to its average volume of 1,521,899. The company has a 50 day moving average of $244.34 and a 200 day moving average of $238.40. The stock has a market cap of $49.36 billion, a PE ratio of 36.21, a price-to-earnings-growth ratio of 1.31 and a beta of 0.51. The company has a current ratio of 0.92, a quick ratio of 0.54 and a debt-to-equity ratio of 16.40. Cencora, Inc. has a 12-month low of $214.77 and a 12-month high of $262.26.
Cencora (NYSE:COR - Get Free Report) last released its quarterly earnings data on Wednesday, February 5th. The company reported $3.73 EPS for the quarter, beating the consensus estimate of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. On average, sell-side analysts forecast that Cencora, Inc. will post 15.37 EPS for the current fiscal year.
Cencora Announces Dividend
The company also recently announced a quarterly dividend, which was paid on Monday, March 3rd. Investors of record on Friday, February 14th were paid a $0.55 dividend. This represents a $2.20 annualized dividend and a dividend yield of 0.86%. The ex-dividend date of this dividend was Friday, February 14th. Cencora's dividend payout ratio is currently 31.29%.
Analysts Set New Price Targets
A number of research analysts have recently issued reports on COR shares. Mizuho started coverage on shares of Cencora in a research report on Wednesday, December 4th. They issued an "outperform" rating and a $280.00 price objective on the stock. StockNews.com downgraded shares of Cencora from a "buy" rating to a "hold" rating in a research report on Tuesday, March 4th. Evercore ISI lifted their price objective on shares of Cencora from $270.00 to $280.00 and gave the stock an "outperform" rating in a research report on Thursday, February 6th. JPMorgan Chase & Co. boosted their target price on shares of Cencora from $289.00 to $301.00 and gave the stock an "overweight" rating in a research report on Friday, January 24th. Finally, Wells Fargo & Company boosted their target price on shares of Cencora from $237.00 to $251.00 and gave the stock an "equal weight" rating in a research report on Wednesday, January 29th. Three analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, Cencora has a consensus rating of "Moderate Buy" and an average target price of $277.90.
Read Our Latest Analysis on COR
Insider Activity at Cencora
In related news, EVP Silvana Battaglia sold 5,000 shares of the business's stock in a transaction on Friday, February 21st. The shares were sold at an average price of $242.24, for a total value of $1,211,200.00. Following the completion of the transaction, the executive vice president now directly owns 15,374 shares in the company, valued at $3,724,197.76. The trade was a 24.54 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Robert P. Mauch sold 4,970 shares of the company's stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $255.00, for a total transaction of $1,267,350.00. Following the transaction, the chief executive officer now owns 51,070 shares of the company's stock, valued at $13,022,850. This represents a 8.87 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 11,648 shares of company stock worth $2,862,342 in the last three months. Company insiders own 10.80% of the company's stock.
About Cencora
(
Free Report)
Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.
Featured Stories
Before you consider Cencora, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cencora wasn't on the list.
While Cencora currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
